Use of new biotechnology to design rational drugs against newly defined targets

Best Practice and Research: Clinical Rheumatology

Volumn 18, Issue 1, 2004, Pages 81-95

  Salfeld, Jochen G ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Antibodies; Biotechnology; Drug discovery; Tumour necrosis factor

Indexed keywords

ABCIXIMAB; ADALIMUMAB; BIOLOGICAL MARKER; G PROTEIN COUPLED RECEPTOR; IMATINIB; METALLOPROTEINASE; PROTEIN P55; PROTEIN P75; PROTEIN SERINE THREONINE KINASE; SERINE PROTEINASE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL MODEL; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; PROTEOMICS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; VALIDATION PROCESS;

EID: 1542346416     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2003.10.001     Document Type: Review

References (42)

1. Drews J. Strategic trends in the drug Industry. Drug Discovery Today 2003; 8: 411-420.
2. van den Haak M, Salek S, Walker SR. New product launches: what will the future bring? Accessed September 24, 2003, at URL www.cmr.org/pio/Handout%20(2%20pages).doc.
3. Gershell LJ & Atkins JH. A brief history of novel drug discovery technology. Nature Reviews in Drug Discovery 2003; 2: 321-327.
4. Zambrowicz BP & Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Reviews in Drug Discovery 2003; 2: 38-51.
5. Knowles J & Gromo G. Target selection in drug discovery. Nature Reviews in Drug Discovery 2003; 2: 63-69.
6. Nowell PC & Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
7. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973; 234: 290-293.
8. Groffen J, Stephenson JR, Heisterkamp N et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
9. Capdeville R, Buchdunger E, Zimmermann & Matter A. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nature Reviews in Drug Discovery 2002; 1: 493-502.
10. Bcr/abl gene of the Phildadelphia Chromosome. Science 1990; 247: 824-830.
11. Nowell PC. Progress with chronic myelogenous leukemia: a personal perspective over four decades. Annual Review of Medicine 2002; 53: 1-13.
12. Carswell EA, Old LJ, Cassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the USA 1975; 72: 3666-3670.
13. Merchant M. More virtual, more throughput, more smaller, more better? Drug Discovery Today 2003; 8: 532-534.
14. Hopkins AL & Groom CR. The druggable genome. Nature Reviews in Drug Discovery 2002; 1: 727-730.
15. 2003 Reopro (abciximab) prescribing information. Centocor, Inc..
16. Baron JH, Moiseeva EP, de Bono DP et al. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 (abciximab): a possible mechanism for influencing restenosis. Cardiovasc Research 2000; 48: 464-472.
17. van Vollenhoven RF & Klareskog L. Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor α followup registry. Arthritis and Rheumatism 2003; 48: 1500-1503.
18. Padyukov L, Lampa J, Heimbuerger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 2003; 62: 526-529.
19. Janssen PA. Drug Research Revue Medicale de Bruxelles 1980; 1: 643-645.
20. Frank R & Hargreaves R. Clinical biomarkers in drug discovery and development. Nature Reviews in Drug Discovery 2003; 2: 566-580.
21. Bleicher KH, Böhm HJ, Müller K & Alanine AI. Hit and lead generation: beyond high-throughput screening. Nature Reviews in Drug Discovery 2003; 2: 369-378.
22. Butcher SP. Target discovery and validation in the post-genomic era. Neurochem Research 2003; 28: 367-371.
23. West DB, Iakougova O, Olsson C et al. Mouse genetics/genomics: an effective approach for drug target discovery and validation. Medicinal Research Reviews 2000; 20: 216-230.
24. Nave BT, Becker M, Roenicke V & Henkel T. Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model. Drug Discovery Today 2002; 7: 419-425.
25. Gossen M & Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annual Review in Genetics 2002; 36: 153-173.
26. Mallo M, Kanzler B & Ohnemus S. Reversible gene inactivation in mouse. Genomics 2003; 81: 356-360.
27. Semizarov D, Frost L, Sarthy A et al. Specificity of short interfering RNA determined through gene expression signatures. Proceedings of the National Academy of Sciences of the USA 2003; 100: 6347-6352.
28. Iyer RP, Kuchimanchi SN & Pandey RK. RNA interference: an exciting new approach for target validation, gene expression analysis and therapeutics. Drugs of the Future 2003; 28: 51-59.
29. Furness LM. Analysis of gene and protein expression for drug mode of toxicity. Current Opinion in Drug Discovery 2002; 5: 98-103.
30. Storck T, von Brevern M, Behrens CK et al. Transcriptomics in predictive toxicology. Current Opinion in Drug Discovery 2002; 5: 90-97.
31. Afshar M. From genes to products: innovations in drug discovery. Drug Discovery Today 2003; 8: 392-394.
32. Reichert JM. Monoclonal antibodies in the clinic. Nature Biotechnology 2001; 19: 819-822.
33. Glennie MJ & van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discovery Today 2003; 8: 503-510.
34. Kohler G & Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1995; 256: 495-497.
35. Cambridge Antibody Technology Group on the World Wide Web URL Accessed September 24, 2003, at www.cambridgeantibody.com.
36. Azzazy HME & Highsmith WE. Phage display technology: clinical applications and recent innovations. Clinical Biochemistry 2001; 35: 425-445.
37. Kellermann SA & Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Current Opinion in Biotechnology 2002; 13: 593-597.
38. Green LL. Antibody engineering via genetic engineering of the mouse: xenomouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. Journal of Immunological Methods 1999; 231: 11-23.
39. Gavilondo JV, Larrick JW. Antibody engineering at the millenium. BioTechniques 2000; 29: 128-45.
40. Machold KP & Smolen JS. Adalimumab - a new TNF-α-antibody for treatment of inflammatory joint disease. Expert Opinion on Biological Therapy 2003; 3: 351-360.
41. Rau R. Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis; the initial results of five trials. Annals of the Rheumatic Diseases 2002; 61 (supplement II): ii70-ii73.
42. Smolen JS & Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews in Drug Discovery 2003; 2: 473-488.